Publication: Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19.
Loading...
Identifiers
Date
2021-07-06
Authors
Buxeda, Anna
Arias-Cabrales, Carlos
Perez-Saez, Maria Jose
Cacho, Judit
Cabello-Pelegrin, Sheila
Melilli, Edoardo
Aladren, Maria Jose
Galeano, Cristina
Lorenzo, Inmaculada
Mazuecos, Auxiliadora
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Abstract
Remdesivir has demonstrated antiviral activity against coronavirus, shortening the time to recovery in adults hospitalized with moderate/severe COVID-19. Severe adverse events such as acute kidney injury have been reported. Scant data are available on the use and safety of remdesivir in kidney transplant recipients. We present a multicenter cohort study of 51 kidney transplant recipients with COVID-19 treated with remdesivir. Outcomes and safety were assessed. Mean age at diagnosis was 60 years, with a median time since kidney transplant of 4.5 years. Mean time since admission to remdesivir was 2 days. Twenty-eight patients (54.9%) required mechanical ventilation (19 noninvasive). Mortality was 18.9% and markedly higher if aged ≥65 years (45% vs. 3.2% in younger patients). Acute kidney injury was present in 27.7% of patients, but was diagnosed in 50% before treatment. No patients required remdesivir discontinuation because of adverse events. We did not find significant hepatoxicity or systemic symptoms resulting from the drug. In our cohort of kidney transplant recipients, remdesivir was well tolerated and safe in renal and hepatic toxicity, but randomized trials are needed to assess its efficacy.
Description
MeSH Terms
Kidney Transplantation
Respiration, Artificial
COVID-19
Acute Kidney Injury
Digestive System Diseases
Antiviral Agents
Cohort Studies
Respiration, Artificial
COVID-19
Acute Kidney Injury
Digestive System Diseases
Antiviral Agents
Cohort Studies
DeCS Terms
Receptores de trasplantes
Lesión Renal Aguda
Respiración artificial
Mortalidad
Antivirales
Lesión Renal Aguda
Respiración artificial
Mortalidad
Antivirales
CIE Terms
Keywords
SARS-CoV2l, Acute kidney injury, Immunosuppression, Kidney transplantation, Remdesivir
Citation
Buxeda A, Arias-Cabrales C, Pérez-Sáez MJ, Cacho J, Cabello Pelegrin S, Melilli E, et al. Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19. Kidney Int Rep. 2021 Sep;6(9):2305-2315